Teva-Gemfibrozil (Teva Canada, 600 mg) Product Monograph

RECENT MAJOR LABEL CHANGES

TABLE OF CONTENTS

RECENT MAJOR LABEL CHANGES ............................................................................................ 2

TABLE OF CONTENTS .............................................................................................................. 2

PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4

1 INDICATIONS ............................................................................................................... 4

1.1 Pediatrics .................................................................................................................... 4

1.2 Geriatrics .................................................................................................................... 4

2 CONTRAINDICATIONS ................................................................................................. 4

4 DOSAGE AND ADMINISTRATION ................................................................................. 5

4.1 Dosing Considerations ................................................................................................ 5

4.2 Recommended Dose and Dosage Adjustment ........................................................... 5

4.4 Administration ............................................................................................................ 5

4.5 Missed Dose ............................................................................................................... 5

5 OVERDOSAGE .............................................................................................................. 5

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ................................. 6

7 WARNINGS AND PRECAUTIONS .................................................................................. 6

7.1 Special Populations .................................................................................................... 8

7.1.1 Pregnant Women ............................................................................................. 8

7.1.2 Breast-feeding .................................................................................................. 8

7.1.3 Pediatrics .......................................................................................................... 8

7.1.4 Geriatrics .......................................................................................................... 9

8 ADVERSE REACTIONS .................................................................................................. 9

8.1 Adverse Reaction Overview ........................................................................................ 9

8.2 Clinical Trial Adverse Reactions .................................................................................. 9

8.5 Post-Market Adverse Reactions ............................................................................... 11

9 DRUG INTERACTIONS ................................................................................................ 12

9.4 Drug-Drug Interactions ............................................................................................. 12

9.5 Drug-Food Interactions ............................................................................................ 13

9.6 Drug-Herb Interactions ............................................................................................. 13

9.7 Drug-Laboratory Test Interactions ........................................................................... 13

10 CLINICAL PHARMACOLOGY ....................................................................................... 13

10.1 Mechanism of Action .............................................................................................. 13

10.2 Pharmacodynamics ................................................................................................ 14

10.3 Pharmacokinetics ................................................................................................... 14

11 STORAGE, STABILITY AND DISPOSAL ......................................................................... 16

12 SPECIAL HANDLING INSTRUCTIONS ........................................................................... 16

PART II: SCIENTIFIC INFORMATION ....................................................................................... 17

13 PHARMACEUTICAL INFORMATION ............................................................................ 17

14 CLINICAL TRIALS ........................................................................................................ 17

14.1 Clinical Trials by Indication ..................................................................................... 17

14.2 Comparative Bioavailability Studies ....................................................................... 22

15 MICROBIOLOGY ........................................................................................................ 23

16 NON-CLINICAL TOXICOLOGY ..................................................................................... 23

17 SUPPORTING PRODUCT MONOGRAPHS .................................................................... 26

PATIENT MEDICATION INFORMATION .................................................................................. 27

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

TEVA-GEMFIBROZIL (gemfibrozil tablet) is indicated in adults as an adjunct to diet and other therapeutic measures for:

• Treatment of patients with very high serum triglyceride levels, Fredrickson classification Type IV and V hyperlipidemias, who are at high risk of sequelae and complications (i.e. pancreatitis) from their hyperlipidemia.
• Treatment of patients with hypercholesterolemia, Type IIa and IIb mixed dyslipidemias, to regulate lipid levels (reduce serum triglycerides and LDL cholesterol levels and increase HDL cholesterol).

TEVA-GEMFIBROZIL alone may not be adequate therapy in some patients with familial combined hyperlipidemia with Type IIb and IV hyperlipoproteinemia.

Initial therapy for hyperlipidemia should include a specific diet, weight reduction, and an exercise program and for patients with diabetes mellitus, a good diabetic control.

Gemfibrozil is not indicated for the treatment of Type I hyperlipoproteinemia.

1.1 Pediatrics

Pediatrics (0 to >18 years): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use.

1.2 Geriatrics

No data is available.

2 CONTRAINDICATIONS

TEVA-GEMFIBROZIL is contraindicated in:

• Patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.
• Patients with hepatic and renal dysfunction, including primary biliary cirrhosis.
• Patients with pre-existing gallbladder disease (see 7 WARNINGS AND PRECAUTIONS).
• Pregnant or breast-feeding patients.
• Concomitant use with the repaglinide (see 9 DRUG INTERACTIONS, Drug-Drug Interactions).
• Concomitant use with simvastatin because of a possible risk of rhabdomyolysis (see 7 WARNINGS AND PRECAUTIONS; 9 DRUG INTERACTIONS, Drug-Drug Interactions).

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

• Initial Therapy: Before instituting gemfibrozil therapy, attempts should be made to control serum lipids and lipoproteins with appropriate diet, exercise, weight loss in obese patients, and control of diabetes mellitus.
• Long-term Therapy: Because long-term administration of gemfibrozil is recommended, pre-treatment clinical chemistry studies should be performed to ensure that the patient has elevated serum lipid or low HDL cholesterol levels. Periodic determinations of serum lipids should be done during gemfibrozil administration, including measurement of LDL-cholesterol/HDL-cholesterol ratio, particularly in Type IV hyperlipoproteinemic patients.
• Since a reduction of total mortality has not been demonstrated, gemfibrozil should be administered only in those patients described in the Indications section.

4.2 Recommended Dose and Dosage Adjustment

The recommended dose for adults is 1200 mg administered in two divided doses (one 600 mg tablet twice a day). The maximum recommended daily dose is 1500 mg.

4.4 Administration

TEVA-GEMFIBROZIL should be administered as a 600 mg tablet twice a day, morning and evening, 30 minutes before the meals.

4.5 Missed Dose

If patient misses a dose, it should be taken immediately unless the time is close to the next dose. In such an event, patient should wait for next scheduled dose and continue on the regular schedule. A double dose should not be taken to make up for a missed dose.

5 OVERDOSAGE

Overdosage has been reported with gemfibrozil. Symptoms reported with overdosage were abdominal cramps, abnormal LFTs, diarrhea, increased CPK, joint and muscle pain, nausea and vomiting. In one case of accidental overdosage, where a child ingested 9 g of gemfibrozil, non- specific symptoms of nausea and vomiting were reported. The patient fully recovered.

Symptomatic supportive measures should be taken should overdosage occur.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 1 – Dosage Forms, Strengths, Composition and Packaging

Description

TEVA-GEMFIBROZIL is available as white, oval shaped, film coated tablets, engraved novo on one side and 600 on the reverse. Available in bottles of 100 tablets.

7 WARNINGS AND PRECAUTIONS

General

If a significant serum lipid response is not obtained in 3 months, TEVA-GEMFIBROZIL should be discontinued.

Gemfibrozil clinically, pharmacologically and chemically shows similarities with clofibrate. Physicians prescribing gemfibrozil should also be familiar with the risks and benefits of clofibrate.

If TEVA-GEMFIBROZIL is chosen for treatment, the prescribing physicians should discuss the proposed therapy and inform the patient of the expected benefits and potential risks which may be associated with long-term administration.

Carcinogenesis and Mutagenesis

No Carcinogenicity or mutagenicity data in humans are available. (See 16 NON-CLINICAL TOXICOLOGY, Carcinogenicity and mutagenicity)

Cardiovascular

Cardiac Arrhythmias:

Although no clinically significant abnormalities occurred that could be attributed to gemfibrozil, the possibility exists that such abnormalities may occur.

Cholesterol

Hematologic

A mild hemoglobin or hematocrit decrease has been observed in occasional patients following initiation of gemfibrozil therapy. The levels then stabilize during long-term administration. Rarely, severe anaemia, leukopenia, thrombocytopenia, eosinophilia and bone marrow hypoplasia have been reported. Therefore, periodic blood count determinations are recommended during the first 12 months of gemfibrozil administration.

Hepatic/Biliary/Pancreatic

Abnormal liver function tests have been observed occasionally during gemfibrozil administration, including elevations of AST, ALT, LDH, and alkaline phosphatase, creatine kinase, bilirubin. These are usually reversible when gemfibrozil is discontinued. Therefore, periodic liver function studies are recommended and gemfibrozil therapy should be terminated if abnormalities persist.

In patients with past history of jaundice or hepatic disorder, gemfibrozil should be used with caution.

Cholelithiasis:

Gemfibrozil may increase cholesterol excretion into the bile leading to cholelithiasis. If cholelithiasis is suspected, gallbladder studies are suggested. TEVA-GEMFIBROZIL (gemfibrozil) should be discontinued if gallstones are found.

Musculoskeletal

Muscle Effects:

There have been reports of severe myalgia, myositis and rhabdomyolysis accompanied by markedly elevated creatinine kinase when gemfibrozil and HMG CoA reductase inhibitors were used concomitantly (see 2 CONTRAINDICATIONS; 9 DRUG INTERACTIONS, Drug-Drug Interactions). When rhabdomyolysis is severe the ensuing myoglobinuria can lead to acute renal failure. Therefore, HMG CoA reductase inhibitors should not be used concomitantly with TEVA-GEMFIBROZIL.

Myopathy, defined as muscle aching or muscle weakness, associated with increases in plasma creatine phosphokinase (CPK) values to greater than 10 times the ULN, should be considered in any patient with diffuse myalgias, muscle tenderness or weakness, and/or marked elevation of CPK. Patients should be advised to report promptly unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever.

The risk of myopathy and rhabdomyolysis during treatment with HGM-CoA reductase inhibitors in combination with fibric acid derivatives is increased. The benefits and risks of combined therapy should be carefully considered see 2 CONTRAINDICATIONS; 9 DRUG INTERACTIONS, Drug-Drug Interactions).

Rhabdomyolysis with renal dysfunction secondary to myoglobinuria have been reported with HMG-CoA reductase inhibitors. Gemfibrozil therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected. Gemfibrozil should be temporarily withheld in any patient experiencing an acute or serious condition suggestive of a myopathy or having a risk factor predisposing to the development of renal failure secondary to rhabdomyolysis, e.g., sepsis; hypotension; major surgery; trauma; severe metabolic, endocrine or electrolyte disorders; or uncontrolled epilepsy.

Reproductive Health: Female and Male Potential

• Fertility

  Administration of approximately 3 and 10 times the human dose to male rats for 10 weeks resulted in a dose-related decrease of fertility. Subsequent studies demonstrated that this effect was reversed after a drug-free period of about 8 weeks, and it was not transmitted to their offspring (16 NON-CLINICAL TOXICOLOGY).

7.1 Special Populations

7.1.1 Pregnant Women

Strict birth control procedures must be exercised by women of childbearing potential. If pregnancy occurs despite birth control procedures, TEVA-GEMFIBROZIL should be discontinued. Women who are planning pregnancy should discontinue gemfibrozil several months prior to conception (16 NON-CLINICAL TOXICOLOGY).

7.1.2 Breast-feeding

Because of the potential for tumorgenicity shown for gemfibrozil in rats, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

7.1.3 Pediatrics

The safety and efficacy of gemfibrozil in children has not been established. Therefore, the use of this drug in this age group is not recommended.

7.1.4 Geriatrics

No data is available.

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

Gemfibrozil has been carefully evaluated in over 3000 patients having received the drug in monitored clinical studies prior to marketing.

The principal symptoms for which incidence was greater with gemfibrozil than with placebo involved the gastrointestinal system. Nausea and vomiting, and abdominal and epigastric pain occurred more often in the gemfibrozil group than in the placebo group. However, the incidence was low: nausea, 4.3% with gemfibrozil versus 3.8% with placebo; vomiting, 2.3% versus 0.8%; abdominal pain, 6.4% versus 4.2%; and epigastric pain, 3.4% versus 1.7%.

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials; therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful in identifying and approximating rates of adverse drug reactions in real-world use.

Symptoms reporting during the controlled phase in studies of 805 subjects were considered for safety. The symptoms listed in Table 2 are those which occurred in at least 5 patients and all skin reactions whatever their incidence.

Table 2 - Incidence of Symptoms Reported in Controlled Pre-Marketing Studies

Additional adverse reactions that have been reported, where a causal relationship to treatment with gemfibrozil is probable are:

Gastrointestinal: Cholestatic jaundice, pancreatitis

Central nervous system: Dizziness, somnolence, peripheral neuritis, depression, decreased libido,

Genitourinary: Impotence

Musculoskeletal: Arthralgia, synovitis, myalgia, myopathy, myasthenia, rhabdomyolysis, (See 7 WARNINGS AND PRECAUTIONS; 9 DRUG INTERACTIONS, Drug-Drug Interactions)

Integumentary: Exfoliative dermatitis, photosensitivity

Immune: Angioedema, laryngeal edema

8.5 Post-Market Adverse Reactions

The long-term safety of gemfibrozil was established in the Helsinki Heart Study, a 5- year primary prevention Phase IV clinical trial. In the double-blind phase of the Helsinki Heart Study 2,046 patients received gemfibrozil for up to 5 years. Table 3 lists the most frequently reported adverse events and includes those occurring in at least 1% of all subjects treated with gemfibrozil. Dyspepsia (19.6% versus 11.9%), abdominal pain (9.8% versus 5.6%), acute appendicitis (1.2% versus 0.6%) and atrial fibrillation (0.7% versus 0.1%) occurred more often in the gemfibrozil group than the placebo group, while all other adverse events were similar in frequency between the two groups.

Table 3 - Incidence of Adverse Events in Controlled Phase of Helsinki Heart Study

9 DRUG INTERACTIONS

9.4 Drug-Drug Interactions

Anticoagulant Drugs:

Caution should be exercised when anticoagulants are given in conjunction with gemfibrozil. The dosage of the anticoagulant should be reduced to maintain the prothrombin time at the desired level to prevent bleeding complications. Frequent prothrombin determinations are advisable until it has been definitely determined that the prothrombin level has stabilized.

Colestipol:

Reduced bioavailability of gemfibrozil may result when given simultaneously with resin-granule drugs such as colestipol. Administration of the drugs two hours or more apart is recommended.

HMG-CoA Reductase Inhibitors:

Use of fibrates, gemfibrozil, alone is occasionally associated with myopathy. The risk of muscle related adverse events including reports of severe myalgia, myositis and rhabdomyolysis accompanied by markedly elevated creatine kinase (CK) were increased when gemfibrozil and HMG-CoA reductase inhibitors, were used concomitantly. When rhabdomyolysis is severe the ensuing myoglobinuria can lead to acute renal failure. Therefore, HMG-CoA reductase inhibitors should not be used concomitantly with gemfibrozil. (see 2 CONTRAINDICATIONS; 7 WARNINGS AND PRECAUTIONS).

Gemfibrozil has been reported to influence the pharmacokinetics of HMG-CoA Reductase Inhibitors including simvastatin, rosuvastatin, atorvastatin, lovastatin, pitavastatin, and pravastatin. Concomitant use of gemfibrozil with simvastatin is contraindicated. Combination therapy of gemfibrozil with rosuvastatin should be avoided. The benefits and risks of combined therapy with atorvastatin and gemfibrozil should be carefully considered and a lower starting and maintenance dose of atorvastatin is recommended if concomitant treatment is required.

Combined drug therapy of gemfibrozil with pravastatin and lovastatin should be used with caution.

Lovastatin:

Repaglinide:

Serious cases of hypoglycemia have been reported following the concomitant use of repaglinide and gemfibrozil. This was likely due to inhibition of CYP 2C8 by gemfibrozil as evidenced by decreases in blood glucose that were proportional to the dose of gemfibrozil. In healthy volunteers, the levels of repaglinide were significantly increased when co-administered with gemfibrozil. The averaged area under the curve (AUC) was increased 8-fold (range 6- to 15-fold) and the half-life increased 3-fold. When itraconazole, an inhibitor of CYP 3A4, was also given with gemfibrozil and repaglinide, even greater effects were observed: AUC for repaglinide was increased 19-fold and the half-life increased from 1.3 to 6 hours.

9.5 Drug-Food Interactions

Interactions with food have not been established.

9.6 Drug-Herb Interactions

Interactions with herbal products have not been established.

9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Gemfibrozil is a lipid regulating agent which decreases serum triglycerides and total cholesterol, and increases high density lipoprotein cholesterol. The lipid-lowering changes occur primarily in the very low density lipoprotein (VLDL) fraction (Sf20 - 400) rich in triglycerides and to a lesser extent in the low density lipoprotein (LDL) fraction (Sf0 - 20) rich in cholesterol. Gemfibrozil treatment of patients with elevated triglycerides due to Type IV hyperlipoproteinemia may cause a rise in LDL-cholesterol. In addition, gemfibrozil increases the high density lipoprotein (HDL) cholesterol subfractions, HDL2 and HDL3, as well as apolipoproteins AI and AII.

Epidemiological studies have shown that both low HDL-cholesterol and high LDL-cholesterol are independent risk factors for coronary heart disease. Depending on the type of hyperlipidemia, pharmacological intervention with gemfibrozil raises HDL-cholesterol and may lower LDL-cholesterol, and may be associated with reduced morbidity due to coronary heart disease as reported in the Helsinki Heart Study, a 5 year primary prevention Phase IV clinical trial (N. Engl.J.Med. 317:1237-1245, 1987).

The mechanism of action of gemfibrozil has not been definitely established. In humans, gemfibrozil has been shown to inhibit peripheral lipolysis and to decrease the hepatic extraction of free fatty acids, thus reducing hepatic triglyceride production. Gemfibrozil also inhibits the synthesis and increases clearance of VLDL carrier apolipoprotein B, leading to a decrease in VLDL.

Animal studies suggest that gemfibrozil may, in addition to elevating HDL cholesterol (HDL-C), reduce incorporation of long-chain fatty acids into newly formed triglycerides, accelerate turnover and removal of cholesterol from the liver, and increase excretion of cholesterol in the feces.

10.2 Pharmacodynamics

The hypolipidemic activity of gemfibrozil has been demonstrated in laboratory animals, with most of the work done with rats. Studies in normal rats showed that gemfibrozil was 15 times more active than clofibrate in reducing triglycerides at doses as low as 7.5 mg/kg over seven days. However, gemfibrozil had no effect on total plasma cholesterol at any dose tested because it increased the HDL fraction by 50% to 70%. Oral doses of 25 mg/kg/day administered to hyperlipidemic rats caused a 75% reduction in the triglyceride level, while clofibrate at four times that dose had no significant effect.

In cholesterol-fed rats with abnormally low HDL cholesterol levels, oral administration of gemfibrozil at doses of 12.5 to 50 mg/kg/day produced elevations in the HDL fraction of 200% to 600%. When lipids were extracted from the liver and measured, it was found that gemfibrozil had caused a dramatic reduction in the liver cholesterol content below the control level at both one and two weeks, suggesting enhanced removal of previously deposited cholesterol.

The mechanism by which these actions occur has not been firmly established. Additional studies in rats suggest that gemfibrozil inhibits the incorporation of long-chain fatty acids into newly formed triglycerides and inhibits basal adipose tissue lipolysis. Gemfibrozil also inhibits the production and increases the turnover rate of the beta-apolipoprotein moiety of VLDL, the resulting decrease in VLDL production providing the basis for the drug's ability to reduce lipid levels.

Gemfibrozil has no significant cardiovascular or central nervous system activity.

10.3 Pharmacokinetics

Absorption

Gemfibrozil is well absorbed from the gastrointestinal tract following oral administration to laboratory animals and humans.

Gemfibrozil is completely absorbed after oral administration, reaching peak plasma concentrations one to two hours after dosing. Gemfibrozil pharmacokinetics are affected by the timing of meals relative to time of dosing. In one study, both the rate and extent of absorption of the drug were significantly increased when administered 0.5 hours before meals. Average AUC was reduced by 14 to 44% when gemfibrozil was administered after meals compared to 0.5 hour before meals. In a subsequent study, rate of absorption of gemfibrozil was maximum when administered 0.5 hour before meals with the C_max 50-60% greater than when given either with meals or fasting. In this study, there were no significant effects on AUC of timing of dose relative to meals.

Metabolism:

Three metabolic pathways have been identified. The first metabolic pathway is that of conjugation of gemfibrozil and its metabolites. The second, and presumably the principal route, involves hydroxylation of the meta-methyl group of gemfibrozil, yielding a benzyl alcohol (Metabolite II) that undergoes rapid oxidation to a benzoic acid metabolite (Metabolite III, the major metabolite). The third pathway involves hydroxylation of the aromatic ring to a phenol (Metabolite I) which is further converted to a compound (Metabolite IV) with no intact carboxylic acid function, but which is phenolic in nature.

Gemfibrozil inhibits CYP2C8 isoenzyme which is involved in the metabolism of several drugs. CYP2C8 inhibition by gemfibrozil can affect the metabolism of several major cardiovascular drugs such as amiodarone, verapamil, warfarin as well as other drugs such as tolbutamide.

Gemfibrozil is also known to potently inhibit CYP2C9 activity. Therefore, CYP2C9 inhibition by gemfibrozil can affect the metabolism of several major cardiovascular drugs such as, carvedilol and losartan as well as other drugs such as diazepam and phenytoin.

Gemfibrozil is highly bound to plasma proteins and there is potential for displacement interactions with other drugs.

Elimination

In animals, gemfibrozil is excreted in both urine and feces. In rats and dogs, the major route of excretion is fecal, accounting for 47% and 62% of a given dose in the two species, respectively. In monkeys, urinary excretion predominates, 62% of an administered dose being excreted by that route in four days; fecal excretion accounted for only 2% of the dose.

In human subjects, approximately 70% of a given dose is excreted in the urine, primarily as the glucuronide conjugate, with less than 2% excreted as unchanged gemfibrozil; 6% of the dose is accounted for in the feces. Peak plasma levels occur in one to two hours following single doses. The mean half-life was approximately 1.5 hours following single doses and 1.3 hours following multiple doses. Plasma levels appear proportional to dose and do not demonstrate accumulation across time following multiple doses.

11 STORAGE, STABILITY AND DISPOSAL

Store between 15°C and 30°C. Keep out of reach and sight of children.

12 SPECIAL HANDLING INSTRUCTIONS

There are no special requirements for use or handling of this product.

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: Gemfibrozil

Chemical name: 5–(2,5–dimethylphenoxy)–2,2–dimethylpentanoic acid

Molecular formula: C₁₅H₂₂O₃

Molecular mass: 250.35 g/mol

Structural formula:

CH 3

O(CH2)3C(CH3)2COOH

CH3

Physicochemical properties: Gemfibrozil is a white, waxy crystalline powder which is stable under ordinary conditions. It has a melting point of 58°C to 61°C. It is very slightly soluble in water and soluble in alcohol, methanol and chloroform.

14 CLINICAL TRIALS

14.1 Clinical Trials by Indication

Hyperlipidemia

Gemfibrozil versus Placebo:

In a large multicentre trial of 427 patients, 108 patients having Fredrickson type IIa, 107 patients, type IIb and 212 patients, type IV hyperlipidemia, the effect of gemfibrozil on lipoprotein fractions was compared to that of placebo. In the initial, controlled phase of the trial, patients were randomly assigned to one of two treatment groups; subjects in group A received placebo for 6 weeks, then received increasing doses of gemfibrozil, 800 mg/day, 1200 mg/day and 1600 mg/day each dose for 6 weeks; those in group B received placebo for the entire period. Following this, the subjects entered a single-blind period in which subjects in group B received the rising doses of gemfibrozil, and those in group A, after 6 weeks on placebo, entered a long-term, open label phase. The following lipid measurements were made: total cholesterol, triglycerides, very low density lipoproteins (VLDL), low density lipoproteins (LDL), and high density lipoproteins (HDL).

Total Cholesterol:

In patients with type IIa and type IIb hyperlipoproteinemia, gemfibrozil therapy resulted in a statistically significant decrease of total cholesterol with all doses, except the 1200 mg dose among the type IIa subjects. In patients with type IV hyperlipidemia, gemfibrozil had no significant effect on total cholesterol.

Triglycerides:

In all three groups of patients, gemfibrozil therapy resulted in a significant decrease of serum triglyceride levels. At the 1200 mg daily dose, triglycerides were decreased by 44% in type IIa patients, by 45% in the type IIb group, and by 40% in type IV patients.

HDL-Cholesterol:

In all three hyperlipoproteinemia types studied, gemfibrozil therapy was associated with a significant elevation of the high density lipoprotein fraction. At the 1200 mg daily dose in type IIa, IIb and type IV patients, the increase of HDL-cholesterol was 24.6%, 19.5% and 17.4%, respectively.

Measurement of HDL-cholesterol to total cholesterol ratio is often employed as a useful parameter in blood lipid profile. This ratio showed a significant increase during gemfibrozil therapy, amounting to 33%, 34% and 23%, respectively, in the three groups studied.

Following the controlled phase of the multicentre trial, 349 subjects entered a long-term open treatment phase with gemfibrozil. Total cholesterol, triglycerides and total LDL-cholesterol levels consistently remained below the baseline placebo values throughout the long-term trial. HDL-cholesterol and the HDL-cholesterol to total cholesterol ratio both consistently remained above the placebo baseline values during the long-term trial. By the end of 12 lunar months of treatment, the improvement in lipid values had increased for nearly every parameter. The greatest changes during the long-term treatment were observed in total cholesterol, LDL-cholesterol, total LDL-cholesterol, and HDL-cholesterol to total cholesterol ratio. These results indicate that the improvement achieved during the control period was maintained or increased during the long-term trial.

Gemfibrozil versus Clofibrate:

The lipid regulating effect of gemfibrozil was also studied against clofibrate. In a study of 32 patients with type IIa, IIb or type IV hyperlipidemia, 17 patients were treated with gemfibrozil, 1200 mg per day, and 15 patients with clofibrate, 2000 mg per day, for 18 weeks. The two drugs had similar effects on total plasma cholesterol, triglycerides and LDL-cholesterol levels, but gemfibrozil had significantly greater effect in elevating HDL-cholesterol and HDL/total cholesterol ratios. The mean percent increases in HDL-cholesterol levels were 22.4% with gemfibrozil and 8.6% with clofibrate, while the HDL/total cholesterol ratio increased 43.0% with gemfibrozil and 25.9% with clofibrate.

Cardiovascular Disease

Primary-Prevention Trial (Helsinki Heart Study):

The Helsinki Heart Study investigated the effect of gemfibrozil on the incidence of coronary heart disease (CHD) in a randomized, double-blind, five-year trial in middle-aged men (40 to 55 years of age) who were free of coronary heart symptoms on entry, but were at a high risk because of abnormal levels of blood lipids (i.e. non-HDL-cholesterol > 200 mg/dl). The study was aimed at testing the hypothesis that reducing serum total cholesterol and LDL-cholesterol, and increasing HDL-cholesterol with gemfibrozil would reduce the incidence of cardiac disease. One group of men (2,046) received 1200 mg (600 mg b.i.d.) of gemfibrozil per day and another group (2,035) received placebo. In terms of Fredrickson types, the subjects entered into the study were distributed as follows:

Table 4 – Distribution of Gemfibrozil and Placebo in Subjects with Fredrickson type IIa, IIb, IV and V

Serum lipids (i.e. total triglycerides, total cholesterol, LDL-cholesterol, and HDL cholesterol) were measured periodically during the study. Efficacy of treatment was determined by comparing the incidence of cardiovascular endpoints (i.e. fatal and non-fatal myocardial infarction, sudden and unwitnessed cardiac death) on an intent-to-treat basis.

Gemfibrozil caused a marked change in the serum lipid levels of patients. The lipid changes occurred rapidly, being noted during the first 3-months of treatment and persisted over the 5-year treatment period. The percent changes in serum lipid levels of the gemfibrozil group by Fredrickson type averaged across the 5-year study period relative to baseline are shown in the following table:

Table 5 – Change of Serum Lipid Levels in Patients

*one subject was a Fredrickson Type V

In the gemfibrozil group, decreases of 37%, 9%, 8%, and 12.5% occurred in triglycerides, total cholesterol, LDL-cholesterol, and non-HDL-cholesterol respectively, and HDL-cholesterol increased by 9%. In contrast, changes in serum lipid levels of the placebo group over the 5-years relative to baseline were small and inconsistent. Statistical analyses revealed a significant difference between the gemfibrozil group and placebo group for every lipid parameter at each year and across all years (p<0.001). Statistical differences were also evident for all lipid parameters between treatment groups by Fredrickson type at each year and across all years (p<0.001), with the exception of LDL-cholesterol in Type IV subjects.

The annual frequency of cardiovascular endpoints over the 5-year study period is shown in the table below:

Table 6 – Summary of Cardiovascular Endpoints Over a 5-year Study Period

¹ MI=myocardial infarction; CD=cardiac death.

² Three subjects in the gemfibrozil group and 6 in the placebo group died later after surviving previous MI.

The effect of gemfibrozil on the incidence of cardiovascular endpoints was first established during the third year and became more prominent over Years 4 and 5 of the study. Analyses of the incidence of cardiovascular endpoints on an intent-to-treat basis revealed that over the 5-year study period, the gemfibrozil group experienced a 34% reduction in the overall incidence of CHD compared to placebo (27.4 per 1,000 in the gemfibrozil group versus 41.3 per 1,000 in the placebo group); in Years 3 to 5 of the study, the reduction in CHD was greater than 50%. There was an overall 37% reduction in non-fatal myocardial infarction (22.0 per 1,000 in the gemfibrozil group versus 34.9 per 1,000 in the placebo group) and a 26% reduction in cardiac deaths (14 deaths in total or 6.8 per 1,000 in the gemfibrozil group versus 19 deaths in total or 9.3 per 1,000 in the placebo group). The greatest reduction in incidence of serious cardiac events occurred in Type IIb patients.

The data from the Helsinki Heart Study suggested that the correlation between changes in lipids (increasing HDL-cholesterol 8.0% and decreasing LDL-cholesterol 7.3%) and reducing CHD incidence should have brought reductions of 23% and 15% respectively in CHD incidence. When the joint effects of HDL-cholesterol (+8.0%) and LDL-cholesterol (-7.3%) were taken into consideration simultaneously, the predicted reduction in CHD incidence was 28% in the gemfibrozil group.

There was no difference between the groups in the total death rate (all causes) over the 5- year study period.

Lithogenicity:

Pre-Marketing Study:

The effect of gemfibrozil on gallstone formation was studied both in normal volunteers and in hyerlipidemic subjects. In 10 healthy male volunteers, gemfibrozil and clofibrate were studied according to a cross-over design. Changes in concentration of bile phospholipid, cholesterol and bile acid were measured and a lithogenic index was calculated. While clofibrate showed a significant potential for lithogenicity, the gemfibrozil results were not significantly different from baseline.

Since the above study suggested a low lithogenic potential for gemfibrozil, further studies were carried out in a group of over 200 patients with dyslipoproteinemias who received gemfibrozil for 2 years or more and who had cholecystograms immediately prior to receiving the drug and at 1 year and 2 year intervals. During the period of study, 5 patients developed radiological evidence of cholelithiasis, an annual incidence of 1.21%. This figure is not different from the incidence of newly observed gallstones in the general population. Based on these data, gemfibrozil does not seem to have a significant lithogenic potential.

Post-Marketing Study:

A gallstone prevalence substudy of 450 Helsinki Heart Study participants showed a trend toward a greater prevalence of gallstones during the study within the gemfibrozil treatment group (7.5% versus 4.9% in the placebo group). In addition, more patients underwent surgical operations (cholecystectomy, cholecystotomy, appendectomy) while on gemfibrozil therapy.

14.2 Comparative Bioavailability Studies

A comparative two-way single-dose bioavailability study was performed on TEVA-GEMFIBROZIL 600 mg Tablets and LOPID® 600 mg Tablets. The pharmacokinetic plasma data (calculated for the 2 formulations) are tabulated below:

Table 7 – Summary Table of the Comparative Bioavailability Data

¹ TEVA-GEMFIBROZIL Tablets, manufactured by Teva Canada Limited

² LOPID 600 mg Tablets, manufactured by Pfizer Canada Inc. and purchased in Canada.

³ Expressed as either the arithmetic mean (CV%)

15 MICROBIOLOGY

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

General Toxicology:

Acute Toxicity:

Table 8 – Toxicity Summary of Single Dose Administration of Gemfibrozil

The effects of single dose gemfibrozil administration to mice and rats showed that the toxicity of the drug was low. Clinical signs of intolerance were similar for both species and included incoordination, depression, flaccid prostration and dyspnea. The only microscopic change was hepatocellular enlargement.

Two beagle dogs were given increasing daily doses of gemfibrozil over a 49-day period. At a dose level of 500 mg/kg, signs of intolerance, such as occasional vomiting and decreased activity, were observed. As the dose level was increased, these symptoms became more frequent and prominent, and finally anorexia, weight loss, and incoordination occurred. One dog died following a dose of 875 mg/kg. At autopsy, congestion and focal mucosal hemorrhage were the only prominent gross findings.

Chronic Toxicity:

Long-term studies with gemfibrozil have been conducted in rats and mice at one and ten times the human dose.

Gemfibrozil was administered to rats and dogs for 12 months. The rats were given daily doses of 30, 150 and 300 mg/kg and the dogs received 25, 150 and 300 mg/kg - the top dose level representing about 15 times the average effective daily human dose.

The 12-month study in rats showed only a dose-related suppression of weight gain. There were fluctuations in hematological and blood biochemical values, but they were neither consistent nor clearly dose-related. Microscopic findings revealed that abnormalities were confined to the liver and consisted primarily of an abundance of microbodies and a marked increase in smooth endoplasmic reticulum in the cell cytoplasm. Such changes are thought to be adaptive rather than degenerative.

In the one-year dog study, gemfibrozil was clinically well-tolerated. Gross autopsy disclosed no drug-related abnormalities. Histopathologic findings revealed that the increase in microbodies, as observed in rats, was not a prominent feature in the hepatocytes of the dogs.

Carcinogenicity: Toxicology studies in male rats revealed a dose-related increase of benign Leydig cell tumors. Subcapsular bilateral cataracts occurred in 10% and unilateral in 6.3% of the high dose males.

Gemfibrozil was given as a dietary admixture at daily doses of 30 and 300 mg/kg to two groups of 50 rats of each sex for 2 years, and another group of 50 rats served as untreated controls. Histologically, the incidence of benign liver nodules and liver carcinomas was significantly increased in high dose male rats. The incidence of liver carcinomas increased also in low dose males, but this increase was not statistically significant (p>0.05). In high dose female rats, there was a significant increase in combined incidence of benign and malignant liver neoplasms. Electron microscopy studies have demonstrated a florid hepatic peroxisome proliferation following gemfibrozil administration to male rats. Similar changes have not been found in the human liver based on biopsy material.

An 18 month study was conducted in mice. Gemfibrozil at daily doses of 30 and 300 mg/kg was given as a dietary admixture to two groups of 72 mice per sex, and an additional group of 72 mice of each sex served as untreated controls. A number of animals died during the course of the study; these deaths were equally distributed among the different groups and no significant differences in mortality rates were found. There were no significant clinical or ophthalmic changes attributable to gemfibrozil. A slight to moderate weight gain suppression occurred in treated animals in a dose related fashion. No histopathological changes were attributed to gemfibrozil except for slight hypertrophy and increased eosinophilia of hepatocytes in the centrolobular area in high dose males. Tumors occurred randomly and there were no statistically significant differences from controls in the incidence of liver tumors in treated male and female mice, but the doses tested were lower than those shown to be carcinogenic with other fibrates.

A comparative carcinogenicity study was also done in rats comparing three drugs in this class: fenofibrate (10 and 60 mg/kg; 0.3 and 1.6 times the human dose), clofibrate (400mg/kg; 1.6 times the human dose), and gemfibrozil (250mg/kg; 1.7 times the human dose). Pancreatic acinar adenomas were increased in males and females on fenofibrate; hepatocellular carcinoma and pancreatic acinar adenomas were increased in males and hepatic neoplastic nodules in females treated with clofibrate; hepatic neoplastic nodules were increased in males and females treated with gemfibrozil while testicular interstitial cell tumors were increased in males on all three drugs.

Mutagenicity: Gemfibrozil was studied under standard test conditions for point mutations by the Ames test. Five strains of Salmonella typhimurium and 3 concentrations of gemfibrozil, (100, 500 and 2500 mcg/plate), with and without metabolic activation, were tested. The resultant number of revertant colonies, in the presence or absence of metabolic activation, was not increased over control at any concentration tested in the five strains. It was concluded that gemfibrozil showed no mutagenic potential in the five strains of Salmonella tested.

Reproductive and Developmental Toxicology: Gemfibrozil was administered in oral doses of approximately 95 and 325 mg/kg/day to male and female rats for 61 and 15 days respectively before mating. Dosing was continued through pregnancy and weaning of offspring. Gemfibrozil produced a dose-related suppression of fertility but had no effect on length of gestation, duration of parturition, litter size, or embryonic or fetal wastage. Treated males were responsible for the reduced fertility rate, probably because of the marked suppression of weight gain they experienced.

Gemfibrozil was administered to pregnant rats and rabbits during the critical period of organogenesis. Rats were given gemfibrozil in the diet in doses of 81 and 281 mg/kg on days 6 through 15 of gestation. Artificially inseminated rabbits were given gemfibrozil by gavage at 60 and 200 mg/kg on days 6 through 18 of gestation. Examination of fetuses removed from treated rats and rabbits one day before expected parturition disclosed no significant effects on either litter or fetal characteristics, nor were significant malformations found among almost 400 offspring from 36 litters of treated rats or 100 fetuses from 22 litters of treated rabbits.

17 SUPPORTING PRODUCT MONOGRAPHS

1. 1. LOPID Tablets, Product Monograph, Pfizer Canada Inc., October 22, 2001.